Education

Browse published references by peptide name. Each entry links to the original article or its PubMed record. The product page provides additional context.

A citation describes the preparation and model studied. Studies of a parent peptide or an individual component do not establish the effects of a modified peptide, a blend, or the finished product. Review study design, limitations and publication status when assessing evidence.

Search by peptide name

5-Amino-1MQ

  1. Dimet-Wiley A, et al. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Sci Rep. 2022;12(1):484. PMID: 35013352 | DOI: 10.1038/s41598-021-03670-5
  2. Akar S, et al. Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells. J Obstet Gynaecol. 2021;41(8):1240-1245. PMID: 33645410 | DOI: 10.1080/01443615.2020.1854696
  3. Yang M, et al. NAD+ metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer. J Immunother Cancer. 2024;12(7):e009281. PMID: 39067875 | DOI: 10.1136/jitc-2024-009281

AOD-9604

  1. Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. PMID: 11146367 | DOI: 10.1159/000053183
  2. Heffernan MA, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449. PMID: 11673763 | DOI: 10.1038/sj.ijo.0801740
  3. Cox HD, et al. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015;7(1):31-38. PMID: 25208511 | DOI: 10.1002/dta.1715

BPC-157

  1. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. PMID: 30915550 | DOI: 10.1007/s00441-019-03016-8
  2. Jozwiak M, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide – Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. PMID: 40005999 | DOI: 10.3390/ph18020185
  3. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-780. PMID: 21030672 | DOI: 10.1152/japplphysiol.00945.2010

BPC+GHK+TB Glow Blend

  1. Chang et al., 2014: BPC-157 in rat tendon fibroblasts (PMID 25415472)
  2. 2023 study: GHK-Cu with hyaluronic acid in fibroblast and skin models (PMID 37062921)
  3. Malinda et al., 1999: thymosin beta-4 in a rat wound model (PMID 10469335)

BPC+GHK+TB+KPV Klow Blend

  1. Chang et al., 2014: BPC-157 in rat tendon fibroblasts (PMID 25415472)
  2. 2023 study: GHK-Cu with hyaluronic acid in fibroblast and skin models (PMID 37062921)
  3. Malinda et al., 1999: thymosin beta-4 in a rat wound model (PMID 10469335)
  4. Dalmasso et al., 2008: KPV uptake and intestinal inflammation (PMID 18061177)

BPC+TB Wolverine Blend

  1. Chang et al., 2014: BPC-157 in rat tendon fibroblasts (PMID 25415472)
  2. Malinda et al., 1999: thymosin beta-4 in a rat wound model (PMID 10469335)

Cagrilintide

  1. Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. PMID: 34798060 | DOI: 10.1016/S0140-6736(21)01751-7
  2. Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021;64(15):11183-11194. PMID: 34288673 | DOI: 10.1021/acs.jmedchem.1c00565
  3. D’Ascanio AM, Mullally JA, Frishman WH. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Cardiol Rev. 2024;32(1):83-90. PMID: 36883831 | DOI: 10.1097/CRD.0000000000000513

Cardiogen

  1. Levdik and Knyazkin, 2009: Cardiogen in a rat M-1 sarcoma model (PMID 20396706)

Cartalax

  1. Caputi S, et al. Effect of short peptides on neuronal differentiation of stem cells. Int J Immunopathol Pharmacol. 2019;33:2058738419828613. PMID: 30791821 | DOI: 10.1177/2058738419828613
  2. Lin’kova NS, et al. Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro. Bull Exp Biol Med. 2016;161(1):175-178. PMID: 27259496 | DOI: 10.1007/s10517-016-3370-x
  3. Khavinson V, Linkova N, Diatlova A, Trofimova S. Peptide Regulation of Cell Differentiation. Stem Cell Rev Rep. 2020;16(1):118-125. PMID: 31808038 | DOI: 10.1007/s12015-019-09938-8

CJC-1295 With DAC

  1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683 | DOI: 10.1210/jc.2005-1536
  2. Memdouh S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021;13(11-12):1871-1887. PMID: 34665524 | DOI: 10.1002/dta.3183
  3. Timms M, et al. An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. Drug Test Anal. 2019;11(6):804-812. PMID: 30489688 | DOI: 10.1002/dta.2554

CJC-1295 Without DAC

  1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683 | DOI: 10.1210/jc.2005-1536
  2. Memdouh S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021;13(11-12):1871-1887. PMID: 34665524 | DOI: 10.1002/dta.3183
  3. Timms M, et al. An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. Drug Test Anal. 2019;11(6):804-812. PMID: 30489688 | DOI: 10.1002/dta.2554

CJC-1295/Ipamorelin Blend

  1. Teichman et al., 2006: long-acting CJC-1295 in healthy adults (PMID 16352683)
  2. Raun et al., 1998: experimental ipamorelin pharmacology (PMID 9849822)

Dihexa

  1. Uribe et al., 2015: Dihexa in zebrafish sensory hair-cell models (PMID 25674052)

DSIP

  1. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006;97(2):303-309. PMID: 16539679 | DOI: 10.1111/j.1471-4159.2006.03693.x
  2. Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): an update. Peptides. 1986;7(6):1165-1187. PMID: 3550726 | DOI: 10.1016/0196-9781(86)90148-8
  3. Pollard BJ, Pomfrett CJD. Delta sleep-inducing peptide. Eur J Anaesthesiol. 2001;18(7):419-422. PMID: 11437870 | DOI: 10.1046/j.1365-2346.2001.00917.x

Epitalon

  1. Khavinson VKh, et al. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID: 12937682 | DOI: 10.1023/a:1025493705728
  2. Khavinson VKh, et al. Peptide promotes overcoming of the division limit in human somatic cell. Bull Exp Biol Med. 2004;137(5):503-506. PMID: 15455129 | DOI: 10.1023/b:bebm.0000038164.49947.8c
  3. Araj SK, et al. Overview of Epitalon – Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci. 2025;26(6):2691. PMID: 40141333 | DOI: 10.3390/ijms26062691

Epitalon Amidate

  1. Khavinson et al., 2003: Epithalon in human fibroblast cultures (PMID 12937682)

Follistatin 344

  1. Chang F, et al. The transgenic expression of human follistatin-344 increases skeletal muscle mass in pigs. Transgenic Res. 2017;26(1):25-36. PMID: 27787698 | DOI: 10.1007/s11248-016-9985-x
  2. Dag U, et al. Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series. Int Ophthalmol. 2020;40(11):3155-3161. PMID: 32671599 | DOI: 10.1007/s10792-020-01501-6
  3. Datta-Mannan A, et al. An engineered human follistatin variant: insights into the pharmacokinetic and pharmacodynamic relationships of a novel molecule with broad therapeutic potential. J Pharmacol Exp Ther. 2013;344(3):616-623. PMID: 23249626 | DOI: 10.1124/jpet.112.201491

FOXO4-DRI

  1. Bourgeois B, et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nat Commun. 2025;16(1):5672. PMID: 40593617 | DOI: 10.1038/s41467-025-60844-9
  2. Kong YX, et al. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Commun Biol. 2025;8(1):299. PMID: 39994346 | DOI: 10.1038/s42003-025-07738-0
  3. Born E, et al. Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression. Circulation. 2023;147(8):650-666. PMID: 36515093 | DOI: 10.1161/CIRCULATIONAHA.122.058794

GHK-Cu

  1. Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-988. PMID: 18644225 | DOI: 10.1163/156856208784909435
  2. Chen H, et al. Food-Derived Tripeptide-Copper Self-Healing Hydrogel for Infected Wound Healing. Biomater Res. 2025;29:0139. PMID: 39902373 | DOI: 10.34133/bmr.0139
  3. Gruchlik A, Chodurek E, Dzierzewicz Z. Effect of Gly-His-Lys and its copper complex on TGF-beta secretion in normal human dermal fibroblasts. Acta Pol Pharm. 2014;71(6):954-958. PMID: 25745767

GHRP-2 Acetate

  1. Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN. Drugs R D. 2004;5(4):236-239. PMID: 15230633 | DOI: 10.2165/00126839-200405040-00011
  2. Laferrere B, et al. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005;90(2):611-614. PMID: 15699539 | DOI: 10.1210/jc.2004-1719
  3. Onuki T, et al. Robust growth hormone responses to GH-releasing peptide 2 in adolescents. J Pediatr Endocrinol Metab. 2024;37(8):730-733. PMID: 38958228 | DOI: 10.1515/jpem-2024-0115

Glutathione

  1. Jomova K, et al. Several lines of antioxidant defense against oxidative stress: antioxidant enzymes, nanomaterials with multiple enzyme-mimicking activities, and low-molecular-weight antioxidants. Arch Toxicol. 2024;98(5):1323-1367. PMID: 38483584 | DOI: 10.1007/s00204-024-03696-4
  2. Barnes PJ. Oxidative stress-based therapeutics in COPD. Redox Biol. 2020;33:101544. PMID: 32336666 | DOI: 10.1016/j.redox.2020.101544

HCG

  1. Esteves SC, et al. Human chorionic gonadotropin-based clinical treatments for infertile men with non-obstructive azoospermia. Andrology. 2026;14(4):1029-1063. PMID: 39901824 | DOI: 10.1111/andr.70003
  2. Chen YW, et al. Testosterone undecanoate supplementation together with human chorionic gonadotropin does not impair spermatogenesis in males with isolated hypogonadotropic hypogonadism: a retrospective study. Asian J Androl. 2019;21(4):413-418. PMID: 30604694 | DOI: 10.4103/aja.aja_107_18
  3. Naelitz BD, et al. Testosterone replacement therapy and spermatogenesis in reproductive age men. Nat Rev Urol. 2025;22(10):703-719. PMID: 40346275 | DOI: 10.1038/s41585-025-01032-8

IGF-1 LR3

  1. Lu Z, et al. Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. Appl Microbiol Biotechnol. 2023;107(14):4543-4551. PMID: 37261455 | DOI: 10.1007/s00253-023-12606-0
  2. Thomas FH, et al. Effects of IGF-I bioavailability on bovine preantral follicular development in vitro. Reproduction. 2007;133(6):1121-1128. PMID: 17636166 | DOI: 10.1530/REP-06-0382
  3. Levolger S, et al. Inhibition of activin-like kinase 4/5 attenuates cancer cachexia associated muscle wasting. Sci Rep. 2019;9(1):9826. PMID: 31285507 | DOI: 10.1038/s41598-019-46178-9

Ipamorelin

  1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822 | DOI: 10.1530/eje.0.1390552
  2. Lu Z, et al. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiol Behav. 2024;284:114644. PMID: 39043357 | DOI: 10.1016/j.physbeh.2024.114644
  3. Aagaard NK, et al. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. Growth Horm IGF Res. 2009;19(5):426-431. PMID: 19231263 | DOI: 10.1016/j.ghir.2009.01.001

Kisspeptin-10

  1. Mills EG, et al. Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans. EBioMedicine. 2025;115:105689. PMID: 40215751 | DOI: 10.1016/j.ebiom.2025.105689
  2. Navarro VM. Metabolic regulation of kisspeptin – the link between energy balance and reproduction. Nat Rev Endocrinol. 2020;16(8):407-420. PMID: 32427949 | DOI: 10.1038/s41574-020-0363-7
  3. Abreu AP, Kaiser UB. Pubertal development and regulation. Lancet Diabetes Endocrinol. 2016;4(3):254-264. PMID: 26852256 | DOI: 10.1016/S2213-8587(15)00418-0

LL-37

  1. Durr UHN, et al. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta. 2006;1758(9):1408-1425. PMID: 16716248 | DOI: 10.1016/j.bbamem.2006.03.030
  2. Verjans ET, et al. Molecular mechanisms of LL-37-induced receptor activation: An overview. Peptides. 2016;85:16-26. PMID: 27609777 | DOI: 10.1016/j.peptides.2016.09.002

Melanotan-II

  1. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. PMID: 16412534 | DOI: 10.1016/j.peptides.2005.01.029
  2. Eliason NL, et al. Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food. Neuropeptides. 2022;96:102289. PMID: 36155088 | DOI: 10.1016/j.npep.2022.102289
  3. Habbema L, et al. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol. 2017;56(10):975-980. PMID: 28266027 | DOI: 10.1111/ijd.13585

MOTS-C

  1. Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Front Endocrinol (Lausanne). 2023;14:1120533. PMID: 36761202 | DOI: 10.3389/fendo.2023.1120533
  2. Yin Y, et al. Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination. Adv Sci (Weinh). 2024;11(43):e2405620. PMID: 39321430 | DOI: 10.1002/advs.202405620
  3. Yin Y, et al. The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus. Pharmacol Res. 2022;175:105987. PMID: 34798268 | DOI: 10.1016/j.phrs.2021.105987

NAD+

  1. Yi L, et al. The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023;45(1):29-43. PMID: 36482258 | DOI: 10.1007/s11357-022-00705-1
  2. Song Q, et al. The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update. Adv Nutr. 2023;14(6):1416-1435. PMID: 37619764 | DOI: 10.1016/j.advnut.2023.08.008

Oxytocin Acetate

  1. Froemke RC, Young LJ. Oxytocin, Neural Plasticity, and Social Behavior. Annu Rev Neurosci. 2021;44:359-381. PMID: 33823654 | DOI: 10.1146/annurev-neuro-102320-102847
  2. Rigney N, de Vries GJ, Petrulis A, Young LJ. Oxytocin, Vasopressin, and Social Behavior: From Neural Circuits to Clinical Opportunities. Endocrinology. 2022;163(9):bqac111. PMID: 35863332 | DOI: 10.1210/endocr/bqac111

PE 22-28

  1. Djillani A, et al. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Front Pharmacol. 2017;8:643. PMID: 28955242 | DOI: 10.3389/fphar.2017.00643
  2. Djillani A, et al. Fighting against depression with TREK-1 blockers: Past and future. A focus on spadin. Pharmacol Ther. 2019;194:185-198. PMID: 30291907 | DOI: 10.1016/j.pharmthera.2018.10.003
  3. Moha Ou Maati H, et al. Spadin as a new antidepressant: absence of TREK-1-related side effects. Neuropharmacology. 2012;62(1):278-288. PMID: 21807005 | DOI: 10.1016/j.neuropharm.2011.07.019

Pinealon

  1. Kozina LS. [Investigation of antihypoxic properties of short peptides]. Adv Gerontol. 2008;21(1):61-67. (Russian) PMID: 18546825
  2. Meshchaninov VN, et al. [Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission]. Adv Gerontol. 2015;28(1):62-67. (Russian) PMID: 26390612
  3. Khavinson V, Linkova N, Kozhevnikova E, Trofimova S. EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer’s Disease. Molecules. 2020;26(1):159. PMID: 33396470 | DOI: 10.3390/molecules26010159

PNC-27

  1. Sarafraz-Yazdi E, et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proc Natl Acad Sci USA. 2010;107(5):1918-1923. PMID: 20080680 | DOI: 10.1073/pnas.0909364107
  2. Sarafraz-Yazdi E, et al. PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis. Biomedicines. 2022;10(5):945. PMID: 35625682 | DOI: 10.3390/biomedicines10050945
  3. Thadi A, et al. Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells. Anticancer Res. 2020;40(9):4857-4867. PMID: 32878773 | DOI: 10.21873/anticanres.14488

Prostamax

  1. Khavinson VKh, Lezhava TA, Malinin VV. Effects of short peptides on lymphocyte chromatin in senile subjects. Bull Exp Biol Med. 2004;137(1):78-81. PMID: 15085253 | DOI: 10.1023/b:bebm.0000024393.40560.05
  2. Meskhi T, et al. [The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ]. Biofizika. 2004;49(6):1091-1093. (Russian) PMID: 15612551
  3. Kiladze M, et al. Microcalorimetric study of human blood lymphocytes culture at presence of copper, cadmium and prostamax. Georgian Med News. 2009;(168):104-107. PMID: 19359734

PT-141

  1. Edinoff AN, et al. Bremelanotide for Treatment of Female Hypoactive Sexual Desire. Neurol Int. 2022;14(1):75-88. PMID: 35076581 | DOI: 10.3390/neurolint14010006
  2. Pettigrew JA, Novick AM. Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment. J Midwifery Womens Health. 2021;66(6):740-748. PMID: 34510696 | DOI: 10.1111/jmwh.13283
  3. Spielmans GI, Ellefson EM. Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder. J Sex Res. 2024;61(4):540-561. PMID: 36809187 | DOI: 10.1080/00224499.2023.2175192

PTD-DBM

  1. Lee SH, et al. Targeting of CXXC5 by a Competing Peptide Stimulates Hair Regrowth and Wound-Induced Hair Neogenesis. J Invest Dermatol. 2017;137(11):2260-2269. PMID: 28595998 | DOI: 10.1016/j.jid.2017.04.038
  2. Ryu YC, et al. CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD2. Cells. 2023;12(4):555. PMID: 36831222 | DOI: 10.3390/cells12040555
  3. Kim D, Garza LA. The Negative Regulator CXXC5: Making WNT Look a Little Less Dishevelled. J Invest Dermatol. 2017;137(11):2248-2250. PMID: 28967390 | DOI: 10.1016/j.jid.2017.07.826

Retatrutide

  1. Abdrabou Abouelmagd A, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Proc (Bayl Univ Med Cent). 2025;38(3):291-303. PMID: 40291085 | DOI: 10.1080/08998280.2025.2456441
  2. Katsi V, et al. Retatrutide – A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15(6):796. PMID: 40563436 | DOI: 10.3390/biom15060796
  3. Locatelli JC, et al. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care. 2024;47(10):1718-1730. PMID: 38687506 | DOI: 10.2337/dci23-0100

Selank

  1. Konstantinopolsky MA, et al. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bull Exp Biol Med. 2022;173(6):730-733. PMID: 36322304 | DOI: 10.1007/s10517-022-05624-x
  2. Kolik LG, et al. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bull Exp Biol Med. 2019;167(5):641-644. PMID: 31625062 | DOI: 10.1007/s10517-019-04588-9
  3. Sarkisova KIu, et al. [Effects of heptapeptide selank on genetically-based and situation-provoked symptoms of depression in behavior in WAG/Rij and Wistar rats, and in BALB/c mice]. Zh Vyssh Nerv Deiat Im I P Pavlova. 2008;58(2):226-237. (Russian) PMID: 18661785

Selank Amidate

  1. 2016 study: parent Selank and neurotransmission-related gene expression in rats (PMID 26924987)

Semaglutide

  1. Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. PMID: 33755728 | DOI: 10.1001/jama.2021.3224
  2. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PMID: 35441470 | DOI: 10.1111/dom.14725

Semax

  1. Medvedeva EV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15(1):228. PMID: 24661604 | DOI: 10.1186/1471-2164-15-228
  2. Panikratova YaR, et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Dokl Biol Sci. 2020;490(1):9-11. PMID: 32342318 | DOI: 10.1134/S001249662001007X

Semax Amidate

  1. 2014 study: parent Semax and gene expression in a rat ischemia model (PMID 24661604)

Sermorelin Acetate

  1. Memdouh S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021;13(11-12):1871-1887. PMID: 34665524 | DOI: 10.1002/dta.3183
  2. Recinella L, et al. Growth hormone-releasing hormone antagonistic analog MIA-690 stimulates food intake in mice. Peptides. 2021;142:170582. PMID: 34051291 | DOI: 10.1016/j.peptides.2021.170582

SLU-PP-332 (injectable)

  1. Billon C, et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther. 2024;388(2):232-240. PMID: 37739806 | DOI: 10.1124/jpet.123.001733
  2. Billon C, et al. Synthetic ERRalpha/beta/gamma Agonist Induces an ERRalpha-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol. 2023;18(4):756-771. PMID: 36988910 | DOI: 10.1021/acschembio.2c00720
  3. Billon C, et al. An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. J Pharmacol Exp Ther. 2026;393(1):103787. PMID: 41421047 | DOI: 10.1016/j.jpet.2025.103787

TB-500

  1. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PMID: 22074294 | DOI: 10.1517/14712598.2012.634793
  2. Philp D, Kleinman HK. Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci. 2010;1194:81-86. PMID: 20536453 | DOI: 10.1111/j.1749-6632.2010.05479.x
  3. Ho ENM, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. PMID: 23084823 | DOI: 10.1016/j.chroma.2012.09.043

Tesamorelin

  1. Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-4304. PMID: 20554713 | DOI: 10.1210/jc.2010-0490
  2. Fourman LT, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020;5(16):e140134. PMID: 32701508 | DOI: 10.1172/jci.insight.140134
  3. Russo SC, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(12):1758-1764. PMID: 38905488 | DOI: 10.1097/QAD.0000000000003965

Thymalin

  1. Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. PMID: 12374906
  2. Khavinson VKh, Morozov VG. [Geroprotective effect of thymalin and epithalamin]. Adv Gerontol. 2002;10:74-84. (Russian) PMID: 12577695
  3. Khavinson VK, et al. Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19. Stem Cell Rev Rep. 2021;17(1):285-290. PMID: 33575961 | DOI: 10.1007/s12015-020-10087-6

Thymosin Alpha-1

  1. Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):879-885. PMID: 11381492 | DOI: 10.1093/ajhp/58.10.886
  2. Goldstein AL. Clinical applications of thymosin alpha-1. Cancer Invest. 1994;12(5):545-547. PMID: 7922712 | DOI: 10.3109/07357909409021415
  3. Dinetz E, Lee E. Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials. Altern Ther Health Med. 2024;30(1):6-12. PMID: 38308608

Tirzepatide

  1. Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. PMID: 34186022 | DOI: 10.1016/S0140-6736(21)01324-6
  2. Nauck MA, et al. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21(1):169. PMID: 36050763 | DOI: 10.1186/s12933-022-01604-7
  3. Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024;15:1431292. PMID: 39114288 | DOI: 10.3389/fendo.2024.1431292

VIP

  1. Voice JK, et al. Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide. Regul Pept. 2002;109(1-3):199-208. PMID: 12409234 | DOI: 10.1016/s0167-0115(02)00182-9
  2. Tang B, et al. Vasoactive intestinal peptide receptor-based imaging and treatment of tumors (Review). Int J Oncol. 2014;44(4):1023-1031. PMID: 24481544 | DOI: 10.3892/ijo.2014.2276
  3. Agibalova T, et al. Vasoactive intestinal peptide promotes secretory differentiation and mitigates radiation-induced intestinal injury. Stem Cell Res Ther. 2024;15(1):348. PMID: 39380035 | DOI: 10.1186/s13287-024-03958-z